Neoadjuvant therapy in non-small cell lung cancer.

Christopher Grant Garo Hagopian Misako Nagasaka

Crit Rev Oncol Hematol

Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Neurology, Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:

Published: October 2023

Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.critrevonc.2023.104080	DOI Listing

Publication Analysis

Top Keywords

non-small cell

cell lung

lung cancer

neoadjuvant therapy

therapy non-small

cancer non-small

cancer nsclc

nsclc stages

stages i-iii

i-iii treated

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!